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Struma ovarii (SO) is a slow-growing ovarian neoplasm with thyroid tissue as its predominant component. It is an
uncommon neoplasm, usually asymptomatic with an unknown risk of malignant transformation. Due to difficulties
in assessing the rare biological nature and the discrepancies in the reported cases, a consensus on the appropriate
treatment has not been definitively reached.
A 50-year-old female was subjected to upper gut endoscopy which showed a 30-mm mass located in the gastric
antrum, suggestive of mesenchimal tumor. Incidentally, a pelvic CT scan also documented a solid mass in the right
adnexa, with morphological characteristics of ovarian neoplasm. The patient underwent gastrectomy, total
hysterectomy, bilateral salpingo-oophorectomy with lymph node dissection, and omentectomy. Histology
documented the presence of gastric cavernous angioma, and, in the right adnexa, foci of follicular thyroid-type
carcinoma arising in SO with a well-differentiated neuroendocrine component.
Here we report and discuss the clinical and morphological presentation of follicular thyroid-type carcinoma arising
in SO. The neoplasm was discovered incidentally and had a favorable clinical outcome at 1-year follow-up.
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Struma ovarii (SO) is a monodermal variant of ovarian
teratoma which predominantly contains thyroid tissue
[1-4]. The incidence is from 0.1% to 0.3% of all ovarian
teratomas [5]. Patients are usually asymptomatic or
predominantly presented with a pelvic mass in 45% of
cases or abdominal pain [5]. Menstrual irregularities and
clinical hyperthyroidism have been demonstrated in 9%
and 5% of cases, respectively [5,6]. Diagnosis of SO is
based on histopathological criteria and guidelines for pri-
mary thyroid gland disease [2,5]. Malignant SO consists
of papillary thyroid carcinoma (PTC) cells, follicular vari-
ant of PTC or follicular thyroid carcinoma (FTC) cells,
and mixed follicular/papillary carcinoma cells [7,8]. The
most common type is PTC, followed by FTC and the re-
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reproduction in any medium, provided the or(HDFCO), characterized by extraovarian dissemination
of thyroid elements [2,4,9]. The differential diagnosis
between benign and malignant neoplasm is still ex-
tremely difficult, in particular for SO with a follicular
growth pattern and undefined capsule. The incidence of
malignancy is also difficult to assess due to the rare na-
ture of this case and the absence of standardized diag-
nostic criteria [5,9]. Malignant transformation has been
reported to vary from 5% to 37% of cases, metastasis is
seen in 23% of cases and it is mainly intra-abdominal [5].
Basing our research on the review of specific scientific
literature, we examined this uncommon case of follicular
thyroid-type carcinoma arising in SO, unsuspected in the
preoperative evaluation.Case report
A 50-year-old female presented to our observation with
epigastric pain. Her past surgical history was uneventful
except for appendectomy. A 30-mm gastric solid mass,
suggestive of mesenchimal tumor, was documented byl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of gastrointestinal bleeding, a biopsy was not indicated.
The CT scan of the abdomen confirmed the presence of
the gastric lesion, and incidentally showed a pelvic mass
of 65×45×60 mm in the right adnexa (Figure 1). The pa-
tient was asymptomatic. The pelvic finding was con-
firmed by US scan: the right ovarian mass had a
prevalent solid component with a rich supply of blood
vessels. No signs or symptoms of hyperthyroidism were
observed. The patient underwent right oophorectomy,
and after intraoperative histological diagnosis of ovarian
carcinoma, a total abdominal hysterectomy with bilateral
salpingo-oophorectomy, retroperitoneal lymph node dis-
section, and omentectomy were finally performed. The
gastric lesion was resected and the digestive continuity
was restored by Billroth’s II anastomosis. At surgery, no
abnormal lymph nodes and ascites were noted. Histology
did not reveal signs of peritoneal carcinomatosis in the
pelvis. Macroscopically the right ovary mass measured
62x45 mm and cut sections showed a solid white-yellow-
ish tissue with focally hemorrhagic areas.
The follicular thyroid-type carcinoma was characterized
by the proliferation of cells arranged in follicular and
trabecular pattern (Figure 2). In the contest of ovarian tera-
toma, the follicular component showed an infiltrative
growth as observed in thyroid carcinoma with moderate
differentiation. The mitotic index was not elevated and any
necrotic tissue areas have been documented. The follicular
tumor border was infiltrated but the cellular growth was
restricted within the capsule. Vascular invasion was
reported in pericapsular capillary structures (Figure 3). To-
gether with the focal follicular thyroid-type carcinoma, the
mature ovarian teratoma showed a well-differentiated neu-
roendocrine component with cells arranged in cordonal-
alveolar structures (Figure 3).
For immunohistochemistry, sections of formalin-fixed
paraffin-embedded samples were treated with H2O2/3%a b
Figure 1 CT appearance of gastric and ovarian neoplasms:
30-mm solid mass with minute calcifications located between the
anterior wall of corpus and gastric antrum (a, arrow). Pelvic mass of
65×45×60 mm on right adnexa suggestive of mixed cystic-solid
ovarian tumor (b).for 5 minutes to inhibit endogenous peroxidase and then
washed in H2O. Antigen was unmasked by treatment with
EDTA at pH 9, or with citrate buffer at pH 6 in a micro-
wave oven (two 5-minutes courses). The slices were then
held for 20 minutes at room temperature. After washing in
PBS/Tween-20, sections were incubated for 30 minutes
with the primary antibodies. Then, they were washed and
stained with BondTM Polymer Refine/HRP Detection Kit
according to the manufacturer’s protocol (Leica, Wetzlar,
Germany) or BondTM Polymer Refine Red Detection Kit
(Leica) for PgR, ER, TTF1, Chromogranin A, Calcitonin,
CD56, CDX2, CEA, CK20. For negative controls, we substi-
tuted non-immune sera for the primary antibodies. The
immunohistochemistry analysis demonstrated positivity for
PgR, TTF1, Chromogranin A, CD56, CDX2, CEA, and
CK20. It was negative for ER and calcitonin. Based on these
specific immunophenotype profile, diagnosis of follicular
thyroid-type carcinoma arising in SO was made (Figures 2
and 3). The multiple peritoneal biopsies and the lymph
nodes were free from metastatic cancer cells. In addition,
peritoneal washing revealed mesothelial cells, leukocytes
but not tumor cells on cytological examination. The defini-
tive diagnosis of gastric neoplasm was cavernous
hemangioma involving submucosa (Figure 3).
The immediate postoperative course was characterized
by anemia treated by medical supporting therapy and
blood transfusions. Postoperative thyroid scan and thyroid
function were normal. She was referred for thyroidectomy
but she refused the operation. Thyroglobulin levels were
monitored in the postoperative period. Nine months after
treatment, laboratory evaluation revealed normal serum
TSH (0.95 mU/L) and thyroglobulin (6.17 ng/mL) levels.
Local and distant recurrences were not observed at the
CT scan evaluation after a follow-up period of 1-year and
the patients was scheduled for further follow-up. During
this period the US of the neck revealed a normal thyroid
gland.
Discussion
Although SO has elicited considerable interest since it was
first described, many diagnostic aspects are still unknown.
SO, defined as containing 50% or more thyroid tissue,
accounts for approximately 5% of all ovarian teratoma, with
an incidence of malignant transformation reported in 5% to
37% of SO [1,10,11]. Most cases are found incidentally and
for this reason the only clinical data are obtained from
retrospective reports. Previous studies have demonstrated
that the majority of patients with SO are asymptomatic or
accompanied by non-specific symptoms similar to other
ovarian neoplasms. At the time of diagnosis, the most
common symptoms were lower abdominal pain, palpable
abdominal mass, ascites, and abnormal vaginal bleeding
[5,12]. Unusual clinical presentations such as hyperthyroid-
ism and Meigs' syndrome have been also documented [2].
a b
c d
Figure 2 Histological and immunohistochemical profile of thyroid type carcinoma in SO. The sections show follicular thyroid cells with the
mucoid glandular component (H&E), ×10 (a); strong and diffuse CD56 reactivity, ×20 (b); Chromogranin A expression in ovarian struma, showing
the neuroendocrine cells × 20 (c); Intrafollicular material and the immunoreactivity for thyroglobulin, ×20 (d).
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to 8% and 17% to 33% of the cases had ascites at diagnosis
[4-6,12,13]. The pathophysiology of hyperthyroidism in
SO is still unknown. Matsuda and colleagues have reported
that malignant SO can be diagnosed before operation bya
c
Figure 3 Histological and immunohistochemical profile of thyroid typ
ovarian teratoma: on the right side mature bone tissue with osteoblasts; on
capillary structures are invaded by cancer cells in the pericapsular area (b, b
cordonal-alveolar pattern (c). Cavernous hemangioma of the stomach arisin
mucosa and muscolaris mucosae, ×20 (d).the evaluation of free T3, and T4, Thyroglobulin, and TSH.
The extremely high levels of Thyroglobulin in local ovarian
venous blood compared with that in peripheral blood pro-
vide evidence of the production of Thyroglobulin in the
ovarian tumor and the normalization of it’s serum levels isb
d
e carcinoma in SO. Microscopical relationship between SO and
the left, follicular thyroid cancer cells, ×20 (a). Vascular invasion:
lack arrows). Neuroendocrine tumor morphology with
g from submucosa: on the lower part of the section, normal gastric
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the patient did not show any specific symptoms and the
diagnosis of SO was incidental and only established after
surgical removal.
Thyroid tissue in SO is morphologically, biochemically
identical to that of cervical thyroid gland. For this reason
the diagnosis of malignant SO is in conformity to the same
criteria used for thyroid carcinoma, such as the presence of
ground glass nuclei, vascular invasion, and mitotic activity
[3]. Unfortunately, the concept of malignant SO in the
literature is confusing due to lack of standardized prognos-
tic parameters. The diagnosis of a well-differentiated variant
is particularly difficult due to lack of a well-defined tumor
capsule in the ovarian tissue. In these cases, the presence of
infiltration by tumor cells into the surrounding ovarian
tissue, and involvement of vascular system, or metastasis,
highly supported the diagnosis of malignancy [2]. Although
the histological aspects of malignancy are often documen-
ted, the majority of patients that underwent surgical treat-
ment for thyroid type carcinoma arising in SO did not
show a clinically aggressive outcome with high rates of
recurrences and metastatic spread. The biological behavior
remains often enigmatic and seems not to be correlated
with the observed long-term clinical outcomes.
With the efforts of understanding the prognostic para-
meters and defining more appropriate treatment care, a
molecular and morphological consensus is advocated to
standardize diagnostic criteria of malignancy in cases of
thyroid type carcinoma in SO.
Distant metastasis has been reported to be a rare feature
of SO in approximately 5% of cases [12]. Other clinical
studies demonstrated a higher intra-abdominal metastatic
rate of 23% [5]. Common metastatic sites are the omentum,
peritoneum, lymph nodes, fallopian tubes, and the contra-
lateral ovary [12]. Some patients presented with distant
metastases to the lungs, bone, brain, liver, and mesenteric
surfaces of the spleen and diaphragm [8,11]. In clinical diag-
nosis, thyroid type carcinoma in SO has to be differentiated
from cystadenoma and other primary ovarian cancers or
metastatic tumors. Generally, SO appeared as a smooth-
margin multicystic mass with a high attenuation signals
during pre-contrast on CT scan. Signal intensities on
T1-weighted images were usually intermediate to high, and
those on T2-weighted images were low as recently reported
by Shen and colleagues [14]. The majority of tumors
showed a mixed cystic and solid mass, with capsule wall
thickness of 3 mm on average, and contained transparent,
green, or brown fluids [14]. To our knowledge five lethal
cases have been reported in literature with recurrences and
metastatic disease [8]. In our case no metastasis have been
documented during 1-year follow-up after surgery.
The treatment of malignant SO remains controversial
and no consensus exists on the surgical and non-surgical
modalities. Surgical treatment consists in total abdominalhysterectomy plus bilateral salpingo-oophorectomy with
omentectomy and lymph nodes sampling, a reasonable
therapy for postmenopausal women with diagnosis of
carcinoma. In other conditions, especially when fertility
has to be preserved, conservative surgery concerning uni-
lateral oophorectomy might be proposed together with a
strict follow-up [5]. This hypothesis should be carefully
discussed with the patients. Laparoscopic surgery may
offer some advantages in surgical staging and its mini-
invasive removal but this technique is not standardized for
these uncommon conditions [6]. After the initial surgery,
some authors have advocated near total thyroidectomy
and radioactive iodine ablation to detect and treat recur-
rent disease [11]. Total thyroidectomy is mandatory to
exclude a primary thyroid neoplasm in the differential
diagnosis of SO. Total thyroidectomy followed by ¹³¹ I
radio ablation therapy should be reserved for patients with
recurrence or residual disease [5,10]. Thyroglobulin is a
well established marker for monitoring the recurrence of
malignancy. An increased serum levels of Thyroglobulin
represent the early detection of recurrence as reported in
many studies [6,11].
SO containing thyroid type carcinoma must be distin-
guished from papillary or follicular thyroid carcinoma
metastatic to the ovary [4]. It is mandatory to study the thy-
roid gland for the differential diagnosis of primary or sec-
ondary tumor of the ovary. De Simone and colleagues have
proposed thyroidectomy to confirm normal thyroid gland,
by excluding a primary thyroid carcinoma, and potentiate
radioactive iodine therapy [3]. No consensus has been
reached in performing prophylactic total thyroidectomy
after the diagnosis of thyroid type carcinoma in SO. In this
situation, the combination of surgical removal with subse-
quent thyroidectomy and radiotherapy do not represent a
standardized therapy but it is a comprehensive therapeutic
modality, still not supported by scientific data in reducing
the risk of recurrence and increase prognostic indices of
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